• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Seattle Genetics

Seattle Genetics

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting

    Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting

  2. Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting

    Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting

  3. Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting

    Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting

  4. Research and Markets: T-Cell Lymphomas - Pipeline Review, H2 2014

    Research and Markets: T-Cell Lymphomas - Pipeline Review, H2 2014

  5. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  6. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

  7. Biotech ETFs: Which One Is Best Now?

    The five biotech ETFs have very different portfolios with markedly different performance.

  8. Our Outlook for Health-Care Stocks

    While we remain bullish on the sector, health-care growth depends on the economy.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.